AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Incyte Genomics Inc
XNAS · usd
SIC 8731 · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
FIGI BBG001S8Q6N2
112.79▲ 0.04 (0.04%)
As of 2026-10-09
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
112.75
Day's Range
111.81 – 113.87
52-Week Range
82.82 – 132.60
Volume
1.1M
Avg Volume
1.6M
Share Statistics
Shares Outstanding
Employees
2,844
Exchange
XNAS
Listed
1993-11-03
Share count as of July 21, 2026

Incyte Genomics Inc (INCY) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Incyte Genomics Inc (INCY)
What is Incyte Genomics Inc's Market Cap?
Incyte Genomics Inc's Market Cap is $22.9B, based on as-reported figures from SEC (XBRL) filings.
What is Incyte Genomics Inc's Enterprise Value?
Incyte Genomics Inc's Enterprise Value is $18.9B, based on as-reported figures from SEC (XBRL) filings.
What is Incyte Genomics Inc's Trailing P/E?
Incyte Genomics Inc's Trailing P/E is 14.2×, based on as-reported figures from SEC (XBRL) filings.
What is Incyte Genomics Inc's Price / Sales?
Incyte Genomics Inc's Price / Sales is 3.9×, based on as-reported figures from SEC (XBRL) filings.
What is Incyte Genomics Inc's EV / Revenue?
Incyte Genomics Inc's EV / Revenue is 3.2×, based on as-reported figures from SEC (XBRL) filings.
What is Incyte Genomics Inc's EV / EBITDA?
Incyte Genomics Inc's EV / EBITDA is 10.1×, based on as-reported figures from SEC (XBRL) filings.
What is Incyte Genomics Inc's Revenue (TTM)?
Incyte Genomics Inc's Revenue (TTM) is $5.8B, based on as-reported figures from SEC (XBRL) filings.
What is Incyte Genomics Inc's Net Income (TTM)?
Incyte Genomics Inc's Net Income (TTM) is $1.6B, based on as-reported figures from SEC (XBRL) filings.
What is Incyte Genomics Inc's EBITDA?
Incyte Genomics Inc's EBITDA is $1.9B, based on as-reported figures from SEC (XBRL) filings.
What is Incyte Genomics Inc's Diluted EPS (TTM)?
Incyte Genomics Inc's Diluted EPS (TTM) is 7.95, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · INCYAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues
YoY growth+37.7%+20.9%+27.8%+20.0%
Costs, expenses and other:
Cost of sales (including definite-lived intangible amortization)
Contract dispute settlement—
Research and development
Selling, general and administrative
Asset impairment and related disposal costs——
Loss on change in fair value of acquisition-related contingent consideration
Total costs, expenses and other
% of revenue58.3%76.3%77.7%67.5%
Income from operations
% of revenue41.7%23.7%22.3%32.5%
Interest income
Interest expense
Gain (loss) on equity investments
Other, net
Income before provision for income taxes
Provision for income taxes
Net income
% of revenue35.0%23.8%19.9%31.1%
Basic (in dollars per share)
Diluted (in dollars per share)